<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00424697</url>
  </required_header>
  <id_info>
    <org_study_id>CRH104150</org_study_id>
    <nct_id>NCT00424697</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Effects of GW876008 on Brain Activation During Emotional Processing in Healthy Subjects.</brief_title>
  <official_title>A Randomized, Placebo-controlled, Double-dummy, Four-way Crossover Design Study to Investigate the Changes of fMRI BOLD Activation Induced by Emotional Activation Paradigms Following Single Doses of GW876008 and Lorazepam (Comparator) in Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      Data suggests that imaging activity of the brain can measure the effects of anti-anxiety&#xD;
      drugs. This study will investigate the effect of GW876008 on areas of the brain involved with&#xD;
      thinking and emotion&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in brain activation elicited by Matching Emotional Face Expression paradigm following single oral doses of GW876008 and lorazepam on day 1, sessions 1-4</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>GW876008 blood levels</measure>
    <time_frame>pre-dose &amp; post-dose, sessions 1-4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical rating scales change after dosing: questionnaires collected</measure>
    <time_frame>pre-dose &amp; up to 6-8 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: 12-lead ECG, vital signs, adverse events, clinical labs</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fMRI BOLD neuroanatomical structure of the emotional brain neurocircuitry and connectivity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fMRI BOLD Signal characteristics and connectivity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fMRI BOLD Response in the emotional brain neurocircuitry and occipital cortex.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ETCo2 in mm Hg, to be recorded for the duration of the scan session and be synchronized with the single fMRI procedure timing</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS) measurements of sleepiness, alertness, calm, tension, and anxiety performed before dosing (baseline), pre-fMRI session, post-fMRI session and just before leaving the facility.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between the anxiety trait (STAI-trait, test battery for neuroticism or liability for Anxiety Disorders) collected at screening and the various pharmacodynamic parameters measured in the various testing conditions.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GW876008 concentration to determine pharmacokinetic parameters to be collected twice per session,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacogenetic (PGx) assessments</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of GW876008 to include Vital signs semi-supine; respiratory rate, pulse oximetry and ECG.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratory tests</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fMRI BOLD ALS signal.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate (HR; beats per minute), to be recorded for the whole duration of the scan session and to be synchronized with the single fMRI procedure timing.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory rate (RR: inspiration per minute), to be recorded for the duration of scan session and be synchronized with the single fMRI procedure timing. .</measure>
  </secondary_outcome>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy Subjects</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lorazepam</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW876008</intervention_name>
    <other_name>placebo</other_name>
    <other_name>lorazepam</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males or females aged 18-50 years, inclusive.&#xD;
&#xD;
          -  STAI-trait score = or &gt; 40.&#xD;
&#xD;
          -  STAI-state score &lt;50th percentile of the normal population distribution.&#xD;
&#xD;
          -  Female subjects of non-childbearing.&#xD;
&#xD;
          -  Female subjects of childbearing potential must agree to use appropriate contraception.&#xD;
&#xD;
          -  Healthy subjects, as determined by a responsible physician&#xD;
&#xD;
          -  Body weight â‰¥ 50 kg (110 lbs), and BMI within the range 19-29.9 kg/m2 inclusive.&#xD;
&#xD;
          -  Demonstrates no significant evidence of active disease, physical or mental impairment&#xD;
             when assessed by qualified personnel&#xD;
&#xD;
          -  Non-smoker (abstinence from smoking for at least 6 months before the start of the&#xD;
             study).&#xD;
&#xD;
          -  Normal electrocardiogram.&#xD;
&#xD;
          -  Capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form.&#xD;
&#xD;
          -  Read, comprehend, and write English at a sufficient level to complete study-related&#xD;
             materials.&#xD;
&#xD;
          -  Provide a signed and dated written informed consent prior to study participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  As a result of any of the medical interview, physical examination, evaluation of&#xD;
             mental state and psychiatric history or screening investigations the physician&#xD;
             responsible considers the subject unfit for the study.&#xD;
&#xD;
          -  Any history of suicidal attempts or behaviour.&#xD;
&#xD;
          -  Any history or current diagnosis of a psychiatric illness.&#xD;
&#xD;
          -  Any history of an endocrine disorder including, but not limited to, diabetes or&#xD;
             disorders of the hypothalamus, pituitary, adrenal, or thyroid glands, or gonadal&#xD;
             disorder or dysfunction of the reproductive organs.&#xD;
&#xD;
          -  Abnormal pepsinogen I level at screening.&#xD;
&#xD;
          -  Liver Function Tests (LFTs) elevated above the reference range at pre-study screening&#xD;
             that remain elevated with a repeat LFT&#xD;
&#xD;
          -  Any other clinically significant laboratory abnormality.&#xD;
&#xD;
          -  Positive faecal occult blood test.&#xD;
&#xD;
          -  Positive pre-study urine drug/alcohol breath screen.&#xD;
&#xD;
          -  Positive pre-study HIV 1/2, Hepatitis B surface antigen and positive Hepatitis C&#xD;
             antibody result within 3 months of the start of the study.&#xD;
&#xD;
          -  Pre-existing or current Helicobactor pylori infection.&#xD;
&#xD;
          -  History of alcohol/drug abuse or dependence within 12 months of the study&#xD;
&#xD;
          -  Consumption of grapefruit juice or grapefruit within 14 days prior to the first dose&#xD;
             of study medication.&#xD;
&#xD;
          -  History of peptic ulcer disease.&#xD;
&#xD;
          -  Abnormal screening ECG&#xD;
&#xD;
          -  History of long QT syndrome (personal or family) or other cardiac conduction disorder,&#xD;
             or other clinically significant cardiac disease.&#xD;
&#xD;
          -  Systolic blood pressure &lt; 90mmHg or &gt;140mmHg; diastolic blood pressure &lt; 60mmHg or &gt;&#xD;
             90mmHg; pulse rate &lt; 40bpm or &gt; 90bpm.&#xD;
&#xD;
          -  Participation in a clinical trial with a drug or new chemical entity within 30 days or&#xD;
             5 half-lives, or twice the duration of the biological effect of any drug (whichever is&#xD;
             longer) prior to the first dose of current study medication.&#xD;
&#xD;
          -  Exposure to more than four new chemical entities within 12 months prior to the first&#xD;
             dosing day.&#xD;
&#xD;
          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary&#xD;
             supplements (including St John's Wort) within 7 days (or 14 days if the drug is a&#xD;
             potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first&#xD;
             dose of study medication.&#xD;
&#xD;
          -  History of sensitivity to any of the study medications, or components thereof or a&#xD;
             history of drug or other allergy that, in the opinion of the physician responsible,&#xD;
             contraindicates their participation.&#xD;
&#xD;
          -  History or current diagnosis of acute narrow angle glaucoma.&#xD;
&#xD;
          -  Where participation in study would result in donation of blood in excess of 500 mL&#xD;
             within a 56 day period.&#xD;
&#xD;
          -  Current or recent (within one year) gastrointestinal disease; a history of&#xD;
             malabsorption, esophageal reflux, irritable bowel syndrome; frequent (more than once a&#xD;
             week) occurrence of heartburn; or any surgical intervention (e.g., cholecystectomy)&#xD;
             which would be expected to influence the absorption of drugs.&#xD;
&#xD;
          -  Average daily caffeine intake equivalent to &gt; 4 cups of coffee or &gt; 6 cups of tea.&#xD;
&#xD;
          -  Subjects who are left handed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials, MBChB, MFPM</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <study_first_submitted>January 17, 2007</study_first_submitted>
  <study_first_submitted_qc>January 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2007</study_first_posted>
  <disposition_first_submitted>October 13, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>October 13, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 15, 2010</disposition_first_posted>
  <last_update_submitted>October 13, 2010</last_update_submitted>
  <last_update_submitted_qc>October 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>Brain imaging,</keyword>
  <keyword>fMRI,</keyword>
  <keyword>stimulation,</keyword>
  <keyword>pharmacodynamics,</keyword>
  <keyword>tolerability,</keyword>
  <keyword>healthy subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lorazepam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

